![](https://webarchive.library.unt.edu/eot2008/20090509170101im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20090509170101im_/http://www.cancer.gov/images/spacer.gif)
hypoxia-activated prodrug TH-302 A hypoxia-activated prodrug consisting of a 2-nitroimidazole phosphoramidate conjugate with potential antineoplastic activity. The 2-nitroimidazole moiety of hypoxia-activated prodrug TH-302 acts as a hypoxic trigger, releasing the DNA-alkylating dibromo isophosphoramide mustard moiety within hypoxic regions of tumors. Normoxic tissues may be spared due to the hypoxia-specific activity of this agent, potentially reducing systemic toxicity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/eot2008/20090509170101im_/http://www.cancer.gov/images/spacer.gif)
Abbreviation: | ![](https://webarchive.library.unt.edu/eot2008/20090509170101im_/http://www.cancer.gov/images/spacer.gif) | HAP TH-302 | | ![](https://webarchive.library.unt.edu/eot2008/20090509170101im_/http://www.cancer.gov/images/spacer.gif) | Code name: | ![](https://webarchive.library.unt.edu/eot2008/20090509170101im_/http://www.cancer.gov/images/spacer.gif) | TH-302 | | ![](https://webarchive.library.unt.edu/eot2008/20090509170101im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20090509170101im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090509170101im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090509170101im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20090509170101im_/http://www.cancer.gov/images/spacer.gif) |